mRNA |
Dasatinib |
FIMM |
pan-cancer |
AAC |
-0.067 |
0.7 |
mRNA |
QL-XII-61 |
GDSC1000 |
pan-cancer |
AAC |
0.016 |
0.7 |
mRNA |
oligomycin a |
CTRPv2 |
pan-cancer |
AAC |
-0.012 |
0.7 |
mRNA |
ABT-199 |
CTRPv2 |
pan-cancer |
AAC |
0.014 |
0.7 |
mRNA |
selumetinib:GDC-0941 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.012 |
0.7 |
mRNA |
AZD1480 |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.7 |
mRNA |
tretinoin:carboplatin (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.7 |
mRNA |
Mdivi-1 |
CTRPv2 |
pan-cancer |
AAC |
-0.012 |
0.7 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.011 |
0.7 |
mRNA |
ruxolitinib |
GDSC1000 |
pan-cancer |
AAC |
-0.011 |
0.8 |